Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role ...

Dear ANCA‑associated vasculitis community, We are writing to share an important update on TAVNEOS® (avacopan) in the European Union (EU). The European Medicines Agency’s (EMA’s) Committee for ...

ST. GALLEN, SWITZERLAND – 26 June 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies ...

CSL Behring’s new facility in Broadmeadows, Victoria, has been named the 2025 Facility of the Year by the International Society for Pharmaceutical Engineering (ISPE), in the Pharma 4.0 category. The ...

Home to CSL’s manufacturing site since the 1950s, funding will support the urgent needs of residents and rebuilding and restoration efforts KING OF PRUSSIA, PA, USA – March 30, 2026 — CSL (ASX:CSL; ...

Read more about An Update on TAVNEOS® (avacopan) in the European Union: Our commitment to continued support for the ANCA Associated Vasculitis Community Large cluster-randomized crossover study ...

Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing,... Large cluster-randomized crossover study ...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a ...